Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

REGN

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:REGN
DateTimeSourceHeadlineSymbolCompany
16/06/202420:10GlobeNewswire Inc.Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple MyelomaNASDAQ:REGNRegeneron Pharmaceuticals Inc
15/06/202406:26Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
14/06/202406:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
13/06/202407:04Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
13/06/202406:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
13/06/202406:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
11/06/202421:00GlobeNewswire Inc.Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)NASDAQ:REGNRegeneron Pharmaceuticals Inc
11/06/202406:03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
08/06/202406:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
07/06/202406:12Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
06/06/202406:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
06/06/202406:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
06/06/202404:24Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
04/06/202406:36Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
31/05/202415:05GlobeNewswire Inc.Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPDNASDAQ:REGNRegeneron Pharmaceuticals Inc
31/05/202415:00GlobeNewswire Inc.Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 InflammationNASDAQ:REGNRegeneron Pharmaceuticals Inc
30/05/202406:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
29/05/202421:15PR Newswire (US)Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial TumorsNASDAQ:REGNRegeneron Pharmaceuticals Inc
29/05/202406:29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
24/05/202407:03GlobeNewswire Inc.Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCONASDAQ:REGNRegeneron Pharmaceuticals Inc
23/05/202406:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
22/05/202406:10Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
21/05/202404:15GlobeNewswire Inc.Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of MedicineNASDAQ:REGNRegeneron Pharmaceuticals Inc
18/05/202407:57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
18/05/202406:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
18/05/202406:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
18/05/202403:45GlobeNewswire Inc.More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024NASDAQ:REGNRegeneron Pharmaceuticals Inc
16/05/202408:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
15/05/202406:21Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
13/05/202415:00GlobeNewswire Inc.Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)NASDAQ:REGNRegeneron Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:REGN

Your Recent History

Delayed Upgrade Clock